Secondary Logo

Institutional members access full text with Ovid®

Association of BMI and height with the risk of endometrial cancer, overall and by histological subtype

a population-based prospective cohort study in Japan

Kawachi, Asukaa,b; Shimazu, Taichia; Budhathoki, Sanjeeva; Sawada, Noriea; Yamaji, Taikia; Iwasaki, Motokia; Inoue, Manamia; Tsugane, Shoichiroa for the JPHC Study Group

European Journal of Cancer Prevention: May 2019 - Volume 28 - Issue 3 - p 196–202
doi: 10.1097/CEJ.0000000000000449
Research Papers: Gynecological Cancer
Buy
SDC

Evidence on the association between BMI, height, and endometrial cancer risk, including by subtypes, among Asian populations remains limited. We evaluated the impact of BMI and height on the risk of endometrial cancer, overall and by histological subtype. We prospectively investigated 53 651 Japanese women aged 40–69 years. With an average follow-up duration of 18.6 years, 180 newly diagnosed endometrial cancers were reported, including 119 type 1 and 21 type 2. The association between BMI, height, and endometrial cancer risk was assessed using a Cox proportional hazards regression model with adjustment for potential confounders. Overweight and obesity were associated positively with the risk of endometrial cancer. Compared with BMI of 23.0–24.9 kg/m2, hazard ratios (HRs) (95% confidence intervals) were 1.93 (1.17–3.16) for BMI of 27.0–29.9 kg/m2 and 2.37 (1.20–4.66) for BMI of at least 30.0 kg/m2. On analysis by histological subtype, with each increase in BMI of 5 U, the estimated HR of type 1 endometrial cancer increased (HR=1.54, 95% confidence interval: 1.21–1.98), but HR of type 2 endometrial cancer was unaffected. There was no statistically significant association between height and endometrial cancer risk. In conclusion, the risk of endometrial cancer was elevated in women with a BMI of at least 27.0 kg/m2. By histological subtype, BMI was associated with type 1, but not type 2 endometrial cancer risk among a population with a relatively low BMI compared with western populations.

aEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center

bDepartment of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Correspondence to Taichi Shimazu, MD, PhD, Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo 104-0045, Japan Tel: +81 33 542 2511; fax: +81 33 547 8578; e-mail: tshimazu@ncc.go.jp

Received September 25, 2017

Accepted March 16, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.